Related Experiment Video
Updated: Jun 3, 2026
Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
Published on: May 1, 2015
Genomics in multiple myeloma
Nikhil C Munshi1, Hervé Avet-Loiseau
1VA Boston Healthcare System, and Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA.
Abstract:
Multiple myeloma (MM) is a complex disease that is driven by numerous genetic and epigenetic alterations. Comprehensive oncogenomic analysis indicates the presence of many highly recurrent and highly focal amplifications and/or deletions in the MM genome. Integrated oncogenomic analyses of human MM have identified candidates resident within regions of amplification and/or deletions that are predicted to be involved in MM pathogenesis and progression. The biological behavior and clinical outcome in MM are dependent on these molecular determinants, which are also attractive therapeutic targets. The data obtained from extensive analysis of patient samples, with annotated clinical outcomes, are providing insights into molecular mechanisms of disease behavior, helping to develop sensitive prognostic models, identifying novel therapeutic targets, providing the framework for the development of molecularly based therapies, and, eventually, will help in developing individualized therapy to improve outcomes, with reduced toxicity.
Insights
Multiple myeloma (MM) is a complex cancer driven by genetic changes. Identifying these genomic alterations in MM is key to developing targeted therapies and improving patient outcomes.
Area of Science:
- Oncogenomics
- Cancer Genetics
- Molecular Biology
Background:
- Multiple myeloma (MM) is a hematologic malignancy characterized by genetic and epigenetic alterations.
- Genomic instability, including amplifications and deletions, is a hallmark of MM development and progression.
Purpose of the Study:
- To identify key genetic alterations in multiple myeloma.
- To understand the role of these alterations in disease pathogenesis and progression.
- To explore the potential of these molecular determinants as therapeutic targets.
Main Methods:
- Comprehensive oncogenomic analysis of human MM samples.
- Integration of genomic data with clinical outcome information.
- Identification of recurrent focal amplifications and deletions.
Main Results:
- Numerous recurrent and focal amplifications/deletions identified in the MM genome.
- Candidate genes within altered regions implicated in MM pathogenesis.
- Correlation between molecular determinants and biological behavior/clinical outcome.
Conclusions:
- Genomic alterations are critical drivers of multiple myeloma.
- Understanding these molecular determinants aids in developing prognostic models.
- Targeting these alterations offers a pathway for novel, individualized MM therapies with reduced toxicity.
More Related Videos
05:32Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
Published on: January 7, 2019
07:24Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube (SWCNT)-delivered MALAT1 Antisense Oligos
Published on: December 13, 2018
